Hasti Nazem is the Co-CEO and Head of Product and Education at Kindra, a New York-based, science-backed women's health brand building estrogen-free solutions for menopause, vaginal health and intimate care. With roughly a decade at the intersection of life sciences, consumer brand-building and wellness, she co-leads the company alongside Afshan Dosani, grounding products in 160+ clinical studies and patent-pending peptide technology. She came to the work through a winding path: a family of physicians, a pre-med start, a detour into finance before the 2008 crash, and a return to school that led her to build wellness companies focused on sleep and, later, women's health.
Noema Pharma is a Basel-based clinical-stage biotech building first-in-disease oral small-molecule therapeutics for central nervous system disorders. Founded in 2019 by Sofinnova Partners around four mid-stage assets in-licensed from Roche, the company targets overlooked neurological conditions - from seizures in tuberous sclerosis complex and pain in trigeminal neuralgia to Tourette syndrome and CNS-mediated symptoms of menopause. It has raised roughly CHF 130 million (about USD 147 million) in Series B financing from a syndicate including Forbion, Jeito Capital, Sofinnova, EQT Life Sciences and UPMC Enterprises.
Origin is a women's health company that makes insurance-covered pelvic floor and whole-body physical therapy widely accessible through a hybrid model of nationwide virtual care and in-person clinics. Founded in 2020 by Carine Carmy, Nona Farahnik Yadegar, and David Yadegar, Origin treats conditions across pregnancy, postpartum, menopause, sexual health, and musculoskeletal pain, and has served over 50,000 patients while shifting pelvic care from a $200-300 cash-pay model to in-network visits that cost most patients under $36.
Alloy Health is a direct-to-consumer women's telehealth company built to fix how medicine treats menopause. Founded by Anne Fulenwider and Monica Molenaar, Alloy connects women in perimenopause and menopause with menopause-trained doctors and a full menu of FDA-approved, science-backed treatments - hormone replacement therapy, vaginal estrogen, plus hair, skin, sexual-wellness, gut and weight solutions - delivered to the door via an asynchronous platform with a flat $50 annual membership. The company raised a $16M Series A in November 2024 and reached profitability while serving women historically dismissed by the healthcare system.
Hone Health is a New York-based telemedicine clinic built for preventive and longevity care. It pairs at-home and in-person testing of 40+ biomarkers with physician-guided treatment plans for hormone optimization, menopause, weight loss, sexual health, thyroid and more, delivered nationwide on a subscription model starting around $129/month. After raising a $33M Series A in January 2025 and acquiring in-home care company ivee, Hone has tested 300,000+ patients and treats roughly 55,000 active members.
Anne Fulenwider spent 25 years turning sentences into magazine covers, capped by eight years as editor-in-chief of Marie Claire. Then she walked away from the masthead to co-found Alloy Women's Health, a digital company that connects women in perimenopause and menopause to menopause-trained physicians and doctor-prescribed treatment delivered to the door. She runs it as co-CEO alongside Monica Molenaar, applying an editor's instinct for storytelling to one of medicine's most overlooked subjects.
Midi Health is a national virtual care clinic built specifically for women in perimenopause, menopause, and the long midlife stretch that mainstream medicine has historically ignored. Founded by Joanna Strober after her own frustrating search for symptom relief, Midi pairs clinicians trained in menopause medicine with an insurance-covered telehealth platform that treats hot flashes, sleep problems, weight changes, mood swings, and long-term hormone health. Now valued above $1 billion after a $100M Series D in February 2026, Midi serves more than 230,000 patients across all 50 states.
Joanna Strober is the co-founder and CEO of Midi Health, the first menopause startup to achieve unicorn status, raising $100M in Series D funding in February 2026 at a $1B+ valuation. A former Bessemer Venture Partners general partner and Sterling Stamos managing director turned entrepreneur, she built Midi Health after her own year-long struggle to get a perimenopause diagnosis in her late 40s. Midi now serves 230,000+ patients across all 50 states through a network of 500+ clinicians, with care covered by approximately 80% of PPOs. Named to TIME100 Health 2025, CNBC Changemakers 2025, and Forbes 50 Over 50 2023, Strober is also a published author (Getting to 50/50) and a former founder of Kurbo Health, the first digital therapeutic for childhood obesity, which she sold to WW.
Mira is a women's health company that built the first at-home hormone monitor with lab-grade accuracy. Its connected device, single-use wands and AI-powered app measure FSH, LH, estrogen (E3G) and PdG so users can map fertility windows, manage PCOS, navigate menopause and share clinical-grade data with their doctors.
Dr. Sophia Yen, MD, MPH is the CEO and Co-Founder of Pandia Health, the only women-founded, women-led, doctor-founded, physician-led birth control and menopause telemedicine and medication delivery service in the United States. A Clinical Associate Professor of Pediatrics at Stanford Medical School with 20+ years in medicine, she brings MIT engineering instincts, UCSF medical training, and UC Berkeley public health expertise to the problem of making prescription contraceptives and hormonal care radically more accessible for women. She co-founded SheHeroes.org to inspire girls in STEM and has been a nationally recognized voice on reproductive rights, menstrual equity, and women's health innovation.
Sylvia Kang is the CEO and co-founder of Mira (Miracare), the company behind the world's first FDA and CE-registered comprehensive at-home hormone monitoring platform. A former concert pianist who pivoted to biomedical engineering, she built Mira from her kitchen table into a 140-person company with 200,000+ users worldwide and over 50,000 women helped to conceive naturally. Named to Inc. Magazine's 2024 Female Founders 250 list and Femtech World's Leader of the Year, Kang holds an MS in Biomedical Engineering from Columbia and an MBA from Cornell, and used her own product to conceive after age 35.